Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Yellowknifer69on Feb 25, 2021 10:05am
284 Views
Post# 32656994

The Job of the CEO

The Job of the CEOHello and good morning Longs:

Just catching up on some light reading whereby a few posters are back to bashing Dan because ATE's SP has declined. I thought I would offer the following commentary;

As a CEO it is my job to manage risk, manage people, and manage money whilst moving the companies' mandate forward - no small feat.

Dan has successfully done this and IMHO has largely stuck to the script.  The unfortunate part of being a junior Bio is just that - we don't have deep pockets and to this point we have had to be very strategic in how we finance our end goals.

I would say the manner in which Antibe achieved the short-term goal of a capital cash raise was executed well and yes, the SP has taken a hit but this too will likely be short lived.

At the end of the day it is The CEO's job is to share the praise with his team when things go really well (like the Nuance deal) and to take all the blame when things go wrong ( bought financing).

However, if you have the patience and are not desperate for money this stock will pay out handsomely. If you don't have patience then cut your losses and move on.  Enough with the moaning already. 

So stay the course longs and lets cut our CEO some slack.  He and his team are working hard and performing well.

Yellowknifer
<< Previous
Bullboard Posts
Next >>